Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints. [electronic resource]
Producer: 20100408Description: 1387-97 p. digitalISSN:- 1873-2968
- Acridines -- pharmacology
- Apoptosis -- drug effects
- Blotting, Western
- Cell Cycle -- drug effects
- Cell Death -- drug effects
- Cyclin B1 -- physiology
- DNA Damage -- drug effects
- Dose-Response Relationship, Drug
- Down-Regulation -- drug effects
- Flow Cytometry
- Gene Expression Regulation -- drug effects
- HeLa Cells -- drug effects
- Humans
- Mitosis -- drug effects
- Poly (ADP-Ribose) Polymerase-1
- Poly(ADP-ribose) Polymerase Inhibitors
- Poly(ADP-ribose) Polymerases -- metabolism
- Polyploidy
- Proteasome Endopeptidase Complex -- drug effects
- Quinazolines -- pharmacology
- Topoisomerase II Inhibitors
- Triazoles -- pharmacology
- Tumor Suppressor Protein p53 -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.